Trials / Completed
CompletedNCT04116073
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
A Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCMGA00012 (PD-1 antibody) | INCMGA00012 (PD-1 antibody): 500 mg, 30 min IV infusion on Day 1 of each cycle (every 28 days) |
Timeline
- Start date
- 2020-04-09
- Primary completion
- 2024-08-06
- Completion
- 2024-12-03
- First posted
- 2019-10-04
- Last updated
- 2025-07-29
- Results posted
- 2025-07-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04116073. Inclusion in this directory is not an endorsement.